BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a partial sequence of human gastric juice protein. First isolated and characterized by Sikiric et al. in the early 1990s at the University of Zagreb, BPC-157 is a stable peptide that resists degradation in gastric acid, an unusual property for a peptide of this size. It has been one of the most extensively studied peptides in preclinical gastroenterology and tissue biology research, with over 100 published animal studies examining its effects across multiple organ systems. BPC-157 has been investigated in models involving the gastrointestinal tract, musculoskeletal tissues, vascular biology, and the nervous system. It is not found in nature in its isolated form but is derived from a larger protective protein present in gastric secretions.

BPC-157 has been investigated for its interactions with multiple signaling pathways in preclinical models. Researchers observed that BPC-157 is associated with upregulation of growth factor receptor expression, including VEGFR2 and FGFR, which may contribute to its studied effects on angiogenesis. Studies suggest that BPC-157 modulates the nitric oxide (NO) system, with evidence of interactions with both NOS enzymes and the NO-cGMP pathway. In gastrointestinal models, researchers observed that BPC-157 is associated with increased expression of tight junction proteins and mucosal protective factors. The peptide has also been investigated for its effects on the FAK-paxillin pathway, which is involved in cell migration and tissue remodeling. In tendon fibroblast studies, BPC-157 was associated with increased expression of growth hormone receptor and collagen-related genes. Additionally, researchers have observed interactions with the dopaminergic and serotonergic systems in neurological models, suggesting broad signaling pathway engagement.

Gastric Cytoprotection

Sikiric et al. (1999) investigated BPC-157 in multiple gastric lesion models in rats, including those induced by ethanol, NSAIDs, and stress. Researchers observed that BPC-157 administration was associated with maintained gastric mucosal integrity and altered expression of protective mucosal factors compared to vehicle controls [1].

Tendon and Ligament Biology

Chang et al. (2011) investigated BPC-157 in a rat Achilles tendon transection model. Researchers observed that treatment was associated with changes in tendon healing parameters, including collagen fiber organization and biomechanical strength, as well as increased growth hormone receptor expression at the injury site [2].

Angiogenesis

Seiwerth et al. (2018) reviewed the angiogenic properties of BPC-157 across multiple preclinical models. Researchers described the peptide’s association with VEGF pathway modulation, endothelial cell tube formation, and vessel density changes in various tissue injury models [3].

Nitric Oxide System

Stupnisek et al. (2015) investigated BPC-157’s interaction with the nitric oxide system in intestinal anastomosis models. Researchers observed that the peptide’s effects were modulated by NOS inhibitors and NO donors, suggesting involvement of the NO-cGMP signaling axis [4].